Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
BETHLEHEM, Pa., Aug. 21, 2017 -- B. Braun Medical Inc. today announced that the U.S. Food and Drug Administration has cleared its hemodialyzer, Diacap® Pro. This new dialyzer has improved clearance performance and user handling.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/03799a24-0338-4711-a708-24c4ed7de1a9
A dialyzer, also known as an “artificial kidney,” is a hemodialysis filter that removes wastes and excess fluid from the blood when a patient’s kidneys can no longer perform the task. Diacap Pro’s advances in fiber technology provide a lower comparable surface area and an increased molecule to surface contact.
“The newly developed fibers in Diacap Pro are designed to improve dialysis dose,” said Samuel Amory, Vice President at B. Braun Medical. “The Diacap Pro fibers clear blood toxins like urea and creatinine, while still retaining vital molecules like albumin. It is our newest hemodialysis product innovation, and fits well with our other products including the Dialog+® Hemodialysis System, Solcart® bicarbonate cartridge, and the AQUAboss® Water Treatment System.”
Diacap Pro is available in three distinct sizes (1.3m2, 1.6m2, 1.9m2), which address the different patient needs.
B. Braun has provided innovative products to the dialysis community for more than 35 years. Its Dialog+ Hemodialysis System incorporates leading-edge technology in dialysis, and its dialysis product line offers an array of disposable products that allow healthcare professionals to tailor treatments for their patients.
To learn more, call the B. Braun Renal Therapies customer service line at 800-848-2066 or visit www.BBraunUSA.com/Diacap.
About B. Braun
B. Braun Medical Inc. markets innovative medical products and services to the healthcare industry. As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone® dialyzers and Medisystems’ Streamline Bloodlines, the Renal Therapies Division of B. Braun is committed to the continued development of high quality products for hemodialysis and continuous renal replacement therapy supported by a team of clinical nurses, field service personnel, customer service and 24/7 technical assistance.
B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.
To learn more about B. Braun Medical, visit www.BBraunUSA.com.
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]
